Search clinical trials for: PHII

Total 78 results

Altec Inc.
University of Nebraska

Not yet recruiting

Adaptive and Individualized AAC Phase II

Communication Disorders
Orca Biosystems, Inc.

Recruiting

Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies (Orca-T)

Acute Myeloid Leukemia | Acute Leukemia | Myelodysplastic Syndrome | Acute Lymphoid Leukemia | Therapy-Related Myelodysplastic Syndrome | Mixed Phenotype Acute Leukemia | Undifferentiated Leukemia

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Metastatic... and other conditions

United States
Mayo Clinic
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaborators

Recruiting

Rare Kidney Stone Consortium Patient Registry (RKSC)

Cystinuria | Primary Hyperoxaluria | Dent Disease | APRT Deficiency

United States, Iceland
National Cancer Institute (NCI)

Active, not recruiting

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Lung Adenocarcinoma | Lung Large Cell Carcinoma | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Minimally Invasive Lung Adenocarcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC v7 | Lung Squamous Cell Carcinoma | Lung Adenocarcinoma, Mixed Subtype

United States
National Cancer Institute (NCI)

Active, not recruiting

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

Metastatic Bladder Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Metastatic Renal Pelvis and Ureter Urothelial Carcinoma

United States
National Cancer Institute (NCI)

Suspended

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

Recurrent Glioblastoma, IDH-Wildtype | MGMT-Methylated Glioblastoma | Recurrent MGMT-Methylated Glioblastoma

United States
AstraZeneca

Active, not recruiting

Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)

Active Systemic Lupus Erythematosus

Thailand, Korea, Republic of, Philippines, China, Taiwan, Hong Kong
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

Mycosis Fungoides | Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8 | Recurrent Mycosis Fungoides... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Unresectable Breast Carcinoma | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction

Metastatic Urothelial Carcinoma | Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Locally Advanced Urothelial Carcinoma | Recurrent Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Advanced Urothelial Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent Ureter Urothelial Carcinoma and other conditions

United States
Laekna Limited

Completed

PhI to Solid Tumors and PhII to Locally Advanced or mTNBC

Solid Tumor | TNBC - Triple-Negative Breast Cancer

China
UNC Lineberger Comprehensive Cancer Center
Bristol-Myers Squibb; Amgen

Active, not recruiting

PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

Colon Cancer

United States
National Cancer Institute (NCI)

Withdrawn

Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia
US Oncology Research
Bristol-Myers Squibb; Pfizer

Active, not recruiting

PhII ICb With/Without Erbitux in MBC Pts (CA225200)

Metastatic Breast Cancer

United States
Hill Dermaceuticals, Inc.
QST Consultations, Ltd.

Completed

Dose-Ranging Study for Miconazole Oil for Treatment of Otomycosis

Otomycosis

United States
National Cancer Institute (NCI)

Completed

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

Advanced Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Advanced Sarcomatoid Renal Cell Carcinoma

United States
Italfarmaco

Terminated

phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients

Hodgkin's Lymphoma

Italy
NPO Petrovax

Completed

Efficacy and Safety of Polyoxidonium, Nasal and Sublingual Spray, 6 mg/ml in Children Aged 1-12 Years With ARI

Acute Respiratory Infection

Russian Federation
Philliber Research & Evaluation
The Office of Adolescent Health, HHS

Unknown

The Evaluation of Achieving Condom Empowerment (ACE)-Plus in New York City

Teen Pregnancy
National Cancer Institute (NCI)

Completed

Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery

Metastatic Urethral Carcinoma | Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage III Ureter Cancer AJCC v7 | Stage III Urethral Cancer AJCC v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Stage IV Ureter Cancer AJCC v7 | Stage IV Urethral Cancer AJCC v7 | Ureter Urothelial Carcinoma and other conditions

United States, Canada
National Cancer Institute (NCI)

Completed

Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer AJCC v7

United States
National Cancer Institute (NCI)

Completed

Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Montefiore Medical Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer

Gastric Cancer | Pancreatic Cancer | Small Intestine Cancer | Liver Cancer | Extrahepatic Bile Duct Cancer | Gastrointestinal Carcinoid Tumor

United States
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma

United States, Taiwan, Australia
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS

Myelodysplastic Syndromes

Italy
National Cancer Institute (NCI)

Completed

PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma

United States
National Cancer Institute (NCI)

Completed

VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Recurrent Melanoma | Stage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage III Melanoma | Extraocular Extension Melanoma

United States
National Cancer Institute (NCI)

Completed

Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder Cancer | Adult Primary Hepatocellular...

United States
National Cancer Institute (NCI)

Terminated

Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery

Advanced Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
National Cancer Institute (NCI)

Completed

AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

PXD101 in Treating Patients With Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions

United States
National Cancer Institute (NCI)

Completed

Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Nodal Marginal Zone Lymphoma

United States
National Cancer Institute (NCI)

Completed

Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
University of Dublin, Trinity College

Completed

Preoperative High Intensity Interval Training: The PHIIT Trial (PHIIT)

Lung Neoplasms | Colorectal Neoplasms

Ireland
Medicines for Malaria Venture

Completed

OZ439 PhIIa Study in Plasmodium Falciparum: Extended Observation

Malaria

Thailand
California Cancer Consortium
National Cancer Institute (NCI)

Terminated

Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer

Kidney Cancer

United States
Anne Beaven, MD
Novartis

Withdrawn

Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies

Hematologic Malignancies

United States
National Cancer Institute (NCI)

Completed

MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy

Lung Adenocarcinoma | Recurrent Non-Small Cell Lung Carcinoma | Adenosquamous Lung Carcinoma | Bronchioloalveolar Carcinoma | Large Cell Lung Carcinoma | Squamous Cell Lung Carcinoma

United States
Lead Chemical Co., Ltd.
Cardinal Health

Completed

Pilot Study Comparing the Efficacy and Safety of a New Pain Patch and Placebo in Delayed Onset Muscle Soreness (DOMS)

Delayed Onset Muscle Soreness

United States
National Cancer Institute (NCI)

Terminated

MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy

Advanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Adult Hepatocellular Carcinoma

United States
National Cancer Institute (NCI)
National Comprehensive Cancer Network

Completed

Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery

Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma

United States
National Cancer Institute (NCI)

Terminated

Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Stage IV Non-Small Cell Lung Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer

Breast Cancer

United States
GlaxoSmithKline

Completed

GSK1358820 (Botulinum Toxin A) PhIII DB & OL Study in Patients With Axillary Hyperhidrosis

Hyperhidrosis

Japan
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

CCI-779 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States, Canada
National Cancer Institute (NCI)

Completed

Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Primary Peritoneal Carcinoma | Stage IV Ovarian Cancer

United States
National Cancer Institute (NCI)

Terminated

Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate

United States

Search clinical trials for: PHII

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations